NCT04220190View on ClinicalTrials.gov

RAPA-501 Therapy for ALS

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 2, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

June 1, 2027

Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIOLOGICAL

RAPA-501 Autologous T stem cells

Experimental: Phase 2/3 Expansion Cohort, Single-agent RAPA-501 T stem cells 80 x 10EE6 cells per infusion (no host conditioning)

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

lead

Rapa Therapeutics LLC

INDUSTRY